RAC - Charts & Price Action, page-11574

Zantrene was past approved for acute myeloid leukaemia. (in France )
Was in trials again on the pathway for approvals and registration elsewhere, notably in the US - but never got to stage of being approved & registered in the US despite completing a lot of the journey, including a phase 3 head to head breast cancer trial there comparing directly with Doxyrubicin , the very ill relapsed breast cancer older women who received Zantrene not Doxorubicin, ultimately all lived longer than the other treatment groups.
(another trial was required for breast cancer there but the US pharmaceutical arm was taken over by an early Wyeth, later by 2010 became Pfizer, but back in the 90s and the process lost)

So far new trials including in acute myeloid leukaemia are very positive!
**See past RAC announcements *
The efficacy for Zantrene for a response and efficacy against refractory and relapsed/ spread (extra - medellary notably ) was remarkable in the 2020 published trials !

Zantrene also has been independently researched by City of hope in the US, Louis Pasteur centre in France , Chicago university, to name a few .
MD Anderson, the no 1 cancer research and treatment facility in the world has also been involved in research.

Dozens of the best world oncology consultants, and specialises and researchers are currently involved with research and advisory in Australia , Europe , US , Israel .

I do not think you know anything wrt Zantrene (eric ) and it is a shame you come in to comment poorly and without sense .

Fundamentals are very strong for RAC .